LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 95 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $974,350 | -31.0% | 671,966 | +6.1% | 0.00% | – |
| Q1 2024 | $1,412,657 | +10.2% | 633,479 | -4.2% | 0.00% | – |
| Q4 2023 | $1,282,373 | +31.9% | 661,017 | -0.1% | 0.00% | – |
| Q3 2023 | $972,495 | -53.6% | 661,561 | +0.4% | 0.00% | – |
| Q2 2023 | $2,096,234 | +35.8% | 659,193 | +0.8% | 0.00% | – |
| Q1 2023 | $1,543,298 | -32.2% | 653,940 | -0.3% | 0.00% | -100.0% |
| Q4 2022 | $2,277,049 | -52.8% | 656,210 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $4,829,000 | +34.9% | 658,756 | +19.9% | 0.00% | 0.0% |
| Q2 2022 | $3,581,000 | +81.8% | 549,261 | +40.8% | 0.00% | – |
| Q1 2022 | $1,970,000 | +256.9% | 390,166 | +447.4% | 0.00% | – |
| Q4 2021 | $552,000 | -36.3% | 71,276 | +21.6% | 0.00% | – |
| Q3 2021 | $867,000 | – | 58,618 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MWG Management Ltd. | 20,162,332 | $69,963,292 | 35.72% |
| Orland Properties Ltd | 15,093,969 | $52,376,072 | 27.91% |
| Foresite Capital Management IV, LLC | 10,000,000 | $34,700,000 | 14.82% |
| MIC Capital Management UK LLP | 3,060,569 | $10,620,174 | 2.10% |
| Alphabet Inc. | 5,865,125 | $20,351,984 | 1.18% |
| HSG Holding Ltd | 3,045,997 | $10,569,610 | 1.07% |
| Artal Group S.A. | 700,000 | $2,429 | 0.14% |
| Eagle Health Investments LP | 100,000 | $347,000 | 0.08% |
| Virtus ETF Advisers LLC | 39,345 | $136,527 | 0.07% |
| BBR PARTNERS, LLC | 164,041 | $569,222 | 0.06% |